Significant publications in diabetes pharmacotherapy and technology in 2020

ABSTRACT

Introduction

The most significant articles on diabetes pharmacotherapy and technology in the peer-reviewed literature from 2020, as determined by a panel of pharmacists with expertise in diabetes care and education, are summarized.

Areas covered

Members of the Association of Diabetes Care and Education Specialists Pharmacy Community of Interest were selected to review articles published in prominent peer-reviewed journals in 2020 that most impacted diabetes pharmacotherapy and technology. A list of 37 nominated articles were compiled (22 in diabetes pharmacotherapy and 15 in diabetes technology). Based on discussion among the authors, the articles were ranked based on significant contribution, impact, and diversity to diabetes pharmacotherapy and technology. The top 10 highest ranked publications (n = 6 for diabetes pharmacotherapy and n = 4 in diabetes technology) are summarized in this article.

Expert opinion

With the significant number of publications in diabetes care and education, it can be challenging and overwhelming to remain current with published literature. This review article may be helpful in identifying key articles in diabetes pharmacotherapy and technology from the year 2020.

KEYWORDS:

• diabetes
• pharmacotherapy
• medications
• technology
• continuous glucose monitors
• insulin pumps

View correction statement:

Notice of duplicate publication: Significant publications in diabetes pharmacotherapy and technology in 2020

Article highlights

• Existing and emerging medications have published evidence for cardiorenal benefit in people with and without diabetes.

• More evidence with pharmacotherapy is needed within special populations, such as those with GDM and T1DM.

• Diabetes technology has emerged as a standard of care for people with T1DM and additional evidence would be valuable for people with T2DM.

• High-impactful articles with a strong methodology have influenced clinical practice guidelines; however, generalizability is a concern due to lack of diversity in clinical trials.

• These selected and summarized articles can serve as a quick review of the clinically significant and impactful articles from the year 2020.

Acknowledgments

The paper represents a collection of publications from 2020, summarized by the authors of the Pharmacy Community of Interest within the Association of Diabetes Care and Education Specialists. The authors would like to acknowledge the leadership team of the Pharmacy Community of Interest of this organization for pursuing and supporting this manuscript.

Declarations

D Isaacs has served on the speaker’s bureau for Dexcom, Abbott, Insulet, Medtronic, Cequr, and Novo Nordisk. She has also served as a consultant to LifeScan, Sanofi, and Lilly.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.